Respiratory support strategies in the prevention of bronchopulmonary dysplasia: A single center quality improvement initiative.
bronchopulmonar dysplasia
caffeine
non-invasive ventilation (NIV)
quality improvement - outcomes
surfactant
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
08
2022
accepted:
02
11
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
30
12
2022
Statut:
epublish
Résumé
Bronchopulmonary dysplasia (BPD) continues to be a significant morbidity affecting very preterm infants, despite multiple advancements in therapies to treat respiratory distress syndrome and prevent BPD. Local quality improvement (QI) efforts have shown promise in reducing unit or system-wide rates of BPD. In preterm infants born between 23- and 32-weeks' gestation, our aim was to decrease the rate of BPD at 36 weeks corrected gestational age from 43% to 28% by January 2019. Directed by a multidisciplinary respiratory QI team, we gradually implemented the following interventions to reach our aim: (1) early initiation of non-invasive ventilation in the delivery room, (2) initiation of caffeine prior to 24 h of life, (3) administration of early selective surfactant per a well-defined guideline, (4) continuation of non-invasive ventilation until 32 and 0/7 weeks corrected gestational age (CGA), and (5) a revision of the early selective surfactant guideline. Outcome measures included rates of BPD, and process measures included compliance with the above interventions. A total of 509 infants with an average gestational age of 29 1/7 weeks and birth weight of 1,254 (SD±401) grams were included. The rate of BPD in our unit decreased from a baseline of 43% to 19% from the start of the project in October 2016 until the first quarter of 2022 ( In preterm infants born between 23- and 32-weeks' gestation, our local QI interventions to reduce rates of BPD were associated with a reduction in rates by 56%. Increased use of antenatal steroids and higher birth weights post- vs. pre-intervention may have contributed to this successes.
Sections du résumé
Background and objectives
UNASSIGNED
Bronchopulmonary dysplasia (BPD) continues to be a significant morbidity affecting very preterm infants, despite multiple advancements in therapies to treat respiratory distress syndrome and prevent BPD. Local quality improvement (QI) efforts have shown promise in reducing unit or system-wide rates of BPD. In preterm infants born between 23- and 32-weeks' gestation, our aim was to decrease the rate of BPD at 36 weeks corrected gestational age from 43% to 28% by January 2019.
Methods
UNASSIGNED
Directed by a multidisciplinary respiratory QI team, we gradually implemented the following interventions to reach our aim: (1) early initiation of non-invasive ventilation in the delivery room, (2) initiation of caffeine prior to 24 h of life, (3) administration of early selective surfactant per a well-defined guideline, (4) continuation of non-invasive ventilation until 32 and 0/7 weeks corrected gestational age (CGA), and (5) a revision of the early selective surfactant guideline. Outcome measures included rates of BPD, and process measures included compliance with the above interventions.
Results
UNASSIGNED
A total of 509 infants with an average gestational age of 29 1/7 weeks and birth weight of 1,254 (SD±401) grams were included. The rate of BPD in our unit decreased from a baseline of 43% to 19% from the start of the project in October 2016 until the first quarter of 2022 (
Conclusions
UNASSIGNED
In preterm infants born between 23- and 32-weeks' gestation, our local QI interventions to reduce rates of BPD were associated with a reduction in rates by 56%. Increased use of antenatal steroids and higher birth weights post- vs. pre-intervention may have contributed to this successes.
Identifiants
pubmed: 36578661
doi: 10.3389/fped.2022.1012655
pmc: PMC9790967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1012655Informations de copyright
© 2022 White, Merritt, Martin, Lauer and Rhein.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Perinatol. 2020 Apr;40(4):681-687
pubmed: 31907398
Qual Saf Health Care. 2003 Dec;12(6):458-64
pubmed: 14645763
Front Pediatr. 2020 May 28;8:270
pubmed: 32548084
J Pediatr. 2022 Apr;243:47-52.e2
pubmed: 34838581
Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9
pubmed: 11401896
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003063
pubmed: 17943779
Pediatrics. 2013 Nov;132(5):e1351-60
pubmed: 24144716
Cochrane Database Syst Rev. 2012 Nov 14;11:CD001456
pubmed: 23152207
Children (Basel). 2021 Apr 15;8(4):
pubmed: 33920871
J Perinatol. 2022 Jan;42(1):58-64
pubmed: 34354227
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753
J Pediatr. 2010 Mar;156(3):382-7
pubmed: 19926098
Cochrane Database Syst Rev. 2016 Jun 14;(6):CD001243
pubmed: 27315509
Semin Fetal Neonatal Med. 2021 Feb;26(1):101201
pubmed: 33563565
Pediatrics. 2005 Dec;116(6):1353-60
pubmed: 16322158
Obstet Gynecol. 2017 Aug;130(2):e102-e109
pubmed: 28742678
J Pediatr. 2020 Feb;217:66-72.e1
pubmed: 31519441
J Appl Physiol (1985). 1996 Oct;81(4):1471-6
pubmed: 8904555
Pediatr Qual Saf. 2019 Aug 09;4(4):e193
pubmed: 31572894
N Engl J Med. 2006 May 18;354(20):2112-21
pubmed: 16707748
JAMA. 2022 Jan 18;327(3):248-263
pubmed: 35040888